HomeCompareCASBF vs PLD

CASBF vs PLD: Dividend Comparison 2026

CASBF yields 51.81% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.47M in total portfolio value· pulled ahead in Year 4
10 years
CASBF
CASBF
● Live price
51.81%
Share price
$3.86
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$7.71
Full CASBF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — CASBF vs PLD

📍 PLD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCASBFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CASBF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CASBF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF
Annual income on $10K today (after 15% tax)
$4,404.15/yr
After 10yr DRIP, annual income (after tax)
$6.55/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,467,964.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + PLD for your $10,000?

CASBF: 50%PLD: 50%
100% PLD50/50100% CASBF
Portfolio after 10yr
$3.27M
Annual income
$2,628,221.94/yr
Blended yield
80.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CASBF
No analyst data
Altman Z
2.6
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys
0
PLD buys
0
No recent congressional trades found for CASBF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCASBFPLD
Forward yield51.81%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%74.4%
Portfolio after 10y$30.0K$6.50M
Annual income after 10y$7.71$5,256,436.18
Total dividends collected$6.0K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CASBF vs PLD ($10,000, DRIP)

YearCASBF PortfolioCASBF Income/yrPLD PortfolioPLD Income/yrGap
1$13,291$2,590.67$11,255$555.24+$2.0KCASBF
2$15,830$1,608.96$13,062$1,018.59+$2.8KCASBF
3$17,834$895.50$15,903$1,926.67+$1.9KCASBF
4← crossover$19,553$471.42$20,839$3,823.32$1.3KPLD
5$21,164$241.53$30,464$8,166.08$9.3KPLD
6$22,767$122.16$52,054$19,457.30$29.3KPLD
7$24,422$61.41$109,886$54,188.93$85.5KPLD
8$26,163$30.78$304,030$186,451.18$277.9KPLD
9$28,010$15.41$1,166,125$840,813.32$1.14MPLD
10$29,978$7.71$6,504,190$5,256,436.18$6.47MPLD

CASBF vs PLD: Complete Analysis 2026

CASBFStock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CASBF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHDCASBF vs JEPICASBF vs OCASBF vs KOCASBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.